Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Learn more:

• clinicaltrials.gov: #NCT03502681
• See Study Information on Big Ten CRC Website